title: Multiparameter phospho-flow analysis of lymphocytes in early rheumatoid arthritis: implications for diagnosis and monitoring drug therapy.
abstract: BACKGROUND
  The precise mechanisms involved in the initiation and progression of rheumatoid arthritis (RA) are not known. Early stages of RA often have non-specific symptoms, delaying diagnosis and therapy. Additionally, there are currently no established means to predict clinical responsiveness to therapy. Immune cell activation is a critical component therefore we examined the cellular activation of peripheral blood mononuclear cells (PBMCs) in the early stages of RA, in order to develop a novel diagnostic modality.
  
  
  RESULTS
  PBMCs were isolated from individuals diagnosed with early RA (ERA) (n = 38), longstanding RA (n = 10), osteoarthritis (OA) (n = 19) and from healthy individuals (n = 10). PBMCs were examined for activation of 15 signaling effectors, using phosphorylation status as a measure of activation in immunophenotyped cells, by flow cytometry (phospho-flow). CD3+CD4+, CD3+CD8+ and CD20+ cells isolated from patients with ERA, RA and OA exhibited activation of multiple phospho-epitopes. ERA patient PBMCs showed a bias towards phosphorylation-activation in the CD4+ and CD20+ compartments compared to OA PBMCs, where phospho-activation was primarily observed in CD8+ cells. The ratio of phospho (p)-AKT/p-p38 was significantly elevated in patients with ERA and may have diagnostic potential. The mean fluorescent intensity (MFI) levels for p-AKT and p-H3 in CD4+, CD8+ and CD20+ T cells correlated directly with physician global assessment scores (MDGA) and DAS (disease activity score). Stratification by medications revealed that patients receiving leflunomide, systemic steroids or anti-TNF therapy had significant reductions in phospho-specific activation compared with patients not receiving these therapies. Correlative trends between medication-associated reductions in the levels of phosphorylation of specific signaling effectors and lower disease activity were observed.
  
  
  CONCLUSIONS
  Phospho-flow analysis identified phosphorylation-activation of specific signaling effectors in the PB from patients with ERA. Notably, phosphorylation of these signaling effectors did not distinguish ERA from late RA, suggesting that the activation status of discrete cell populations is already established early in disease. However, when the ratio of MFI values for p-AKT and p-p38 is >1.5, there is a high likelihood of having a diagnosis of RA. Our results suggest that longitudinal sampling of patients undergoing therapy may result in phospho-signatures that are predictive of drug responsiveness.
authors.affiliation: Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada.
authors.forename: Carole L
authors.initials: CL
authors.lastname: Galligan
authors.forename: Janet C
authors.initials: JC
authors.lastname: Siebert
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Siminovitch
authors.forename: Edward C
authors.initials: EC
authors.lastname: Keystone
authors.forename: Vivian
authors.initials: V
authors.lastname: Bykerk
authors.forename: Omar D
authors.initials: OD
authors.lastname: Perez
authors.forename: Eleanor N
authors.initials: EN
authors.lastname: Fish
mesh_terms: D000328:Adult; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D016903:Drug Monitoring; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D008214:Lymphocytes / Q000276:immunology / Q000473:pathology*; D008297:Male; D010766:Phosphorylation
references.citation: J Pharmacol Exp Ther. 1995 Nov;275(2):1043-9
references.pmid: 7473131
references.citation: Rheum Dis Clin North Am. 2001 May;27(2):269-81
references.pmid: 11396092
references.citation: Nat Chem Biol. 2008 Feb;4(2):132-42
references.pmid: 18157122
references.citation: Clin Exp Rheumatol. 2005 Mar-Apr;23(2):243-6
references.pmid: 15895898
references.citation: Transplantation. 1996 Jan 15;61(1):140-5
references.pmid: 8560553
references.citation: J Immunol. 1999 Feb 15;162(4):2095-102
references.pmid: 9973483
references.citation: J Exp Med. 2008 Jul 7;205(7):1543-50
references.pmid: 18591412
references.citation: Arthritis Res Ther. 2008;10(6):R147
references.pmid: 19099567
references.citation: Arthritis Rheum. 2005 Nov;52(11):3381-90
references.pmid: 16258899
references.citation: Lancet. 1998 Nov 7;352(9139):1498-504
references.pmid: 9820297
references.citation: J Immunol. 2008 May 1;180(9):6070-6
references.pmid: 18424728
references.citation: Cytometry A. 2003 Oct;55(2):61-70
references.pmid: 14505311
references.citation: N Engl J Med. 2000 Nov 30;343(22):1586-93
references.pmid: 11096165
references.citation: Clin Rheumatol. 2009 Jan;28(1):17-21
references.pmid: 18663553
references.citation: Transplantation. 1993 Jun;55(6):1361-6
references.pmid: 8390735
references.citation: Arthritis Rheum. 2009 Jun;60(6):1647-56
references.pmid: 19479869
references.citation: Rheumatology (Oxford). 2003 Feb;42(2):268-75
references.pmid: 12595621
references.citation: Arthritis Res Ther. 2005;7(4):R784-95
references.pmid: 15987480
references.citation: J Clin Invest. 1994 Aug;94(2):749-60
references.pmid: 8040330
references.citation: Cell. 2004 Jul 23;118(2):217-28
references.pmid: 15260991
references.citation: J Immunol. 2000 Apr 1;164(7):3894-901
references.pmid: 10725752
references.citation: J Rheumatol Suppl. 2007 Nov;80:1-7
references.pmid: 17985417
references.citation: Ann Rheum Dis. 2004 Sep;63(9):1090-5
references.pmid: 15308518
references.citation: Arthritis Res Ther. 2008;10 Suppl 1:S5
references.pmid: 19007425
references.citation: Arthritis Rheum. 2000 Nov;43(11):2501-12
references.pmid: 11083274
references.citation: Transplantation. 1996 Feb 27;61(4):635-42
references.pmid: 8610393
references.citation: Arthritis Rheum. 2000 Feb;43(2):464-5
references.pmid: 10693890
references.citation: Arthritis Rheum. 2004 Mar;50(3):794-804
references.pmid: 15022321
references.citation: Lancet. 2001 Sep 15;358(9285):903-11
references.pmid: 11567728
references.citation: J Virol. 2007 Aug;81(15):7860-72
references.pmid: 17522202
references.citation: Blood. 2007 Mar 15;109(6):2589-96
references.pmid: 17105820
references.citation: Rheumatology (Oxford). 2003 Jan;42(1):89-96
references.pmid: 12509619
references.citation: J Rheumatol. 2007 Nov;34(11):2285-90
references.pmid: 17937463
references.citation: Bull NYU Hosp Jt Dis. 2007;65(3):168-73
references.pmid: 17922664
references.citation: Mol Immunol. 2004 Jul;41(6-7):687-700
references.pmid: 15220004
references.citation: J Clin Rheumatol. 2005 Jun;11(3 Suppl):S39-44
references.pmid: 16357749
references.citation: Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S65-70
references.pmid: 14969053
references.citation: J Immunol. 2008 Jul 15;181(2):1190-8
references.pmid: 18606672
references.citation: Arthritis Rheum. 2008 Aug;58(8):2241-7
references.pmid: 18668546
references.citation: N Engl J Med. 2005 Sep 15;353(11):1114-23
references.pmid: 16162882
references.citation: Arthritis Rheum. 2007 May;56(5):1424-32
references.pmid: 17469099
references.citation: Curr Opin Investig Drugs. 2003 May;4(5):572-7
references.pmid: 12833651
references.citation: Arthritis Rheum. 1988 Mar;31(3):315-24
references.pmid: 3358796
references.citation: Ann Rheum Dis. 2006 Dec;65(12):1558-64
references.pmid: 16760256
references.citation: Ann Rheum Dis. 2009 Oct;68(10):1644-50
references.pmid: 18957484
references.citation: Br Med Bull. 1995 Apr;51(2):286-95
references.pmid: 7552064
references.citation: Ann Rheum Dis. 2005 Aug;64(8):1199-204
references.pmid: 15640269
references.citation: Methods Mol Biol. 2004;263:67-94
references.pmid: 14976361
references.citation: Arthritis Rheum. 1994 Apr;37(4):481-94
references.pmid: 8147925
references.citation: Clin Immunol. 2004 Mar;110(3):206-21
references.pmid: 15047199
references.citation: Clin Exp Immunol. 2008 May;152(2):372-80
references.pmid: 18341611
references.citation: J Rheumatol. 2001 Aug;28(8):1793-9
references.pmid: 11508581
references.citation: Ann Rheum Dis. 2003 Feb;62(2):120-6
references.pmid: 12525380
references.citation: Biomed Pharmacother. 2006 Dec;60(10):648-55
references.pmid: 17064873
references.citation: N Engl J Med. 2004 Jun 17;350(25):2572-81
references.pmid: 15201414
references.citation: Ann Rheum Dis. 2009 Jul;68(7):1184-91
references.pmid: 18728049
references.citation: J Immunol. 2007 Mar 15;178(6):3427-36
references.pmid: 17339437
references.citation: Ann Rheum Dis. 2009 Sep;68(9):1482-5
references.pmid: 19015211
references.citation: J Immunol. 1998 Feb 15;160(4):1581-8
references.pmid: 9469413
references.citation: J Immunol. 2001 Oct 15;167(8):4710-8
references.pmid: 11591802
references.citation: J Clin Invest. 1995 Sep;96(3):1631-8
references.pmid: 7657832
references.citation: Arthritis Rheum. 2002 Nov;46(11):2847-56
references.pmid: 12428224
references.citation: Ann Rheum Dis. 2003 May;62(5):440-3
references.pmid: 12695157
references.citation: J Cell Sci. 2003 Sep 15;116(Pt 18):3677-85
references.pmid: 12917355
references.citation: Arthritis Rheum. 2000 Jan;43(1):22-9
references.pmid: 10643696
references.citation: Cell Immunol. 1992 Oct 15;144(2):347-57
references.pmid: 1356636
references.citation: Ann N Y Acad Sci. 2008 Nov;1143:268-85
references.pmid: 19076355
references.citation: Rheumatology (Oxford). 2008 Apr;47(4):399-402
references.pmid: 18263596
references.citation: Ann Rheum Dis. 1997 Jan;56(1):27-31
references.pmid: 9059137
references.citation: Ann Rheum Dis. 2005 Jan;64(1):38-43
references.pmid: 15130899
references.citation: Nat Methods. 2006 May;3(5):361-8
references.pmid: 16628206
references.citation: Science. 1995 Oct 13;270(5234):286-90
references.pmid: 7569976
references.citation: Bull NYU Hosp Jt Dis. 2008;66(3):210-5
references.pmid: 18937634